Clin Osteol 2009; 14(4): 156-160

Efect of ezetimibe on the bone metabolism in ratsGuidelines

I. Gradošová, K. Josefová, H. Živná, P. Živný, V. Palička

Keywords: ezetimib, PINP, ICTP, OC, BALP v SUMMARY

Published: December 11, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gradošová I, Josefová K, Živná H, Živný P, Palička V. Efect of ezetimibe on the bone metabolism in rats. Osteologický bulletin. 2009;14(4):156-160.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McCormick RK. Osteoporosis: integrating biomarkers and other diagnostic corre­ lates into the management of bone fragility. Alter Med Rev 2007;12(2):113-145.
    2. Poole KE, Compston JE. Osteoporosis and its management. BMJ 2006;333(7581):1251-1256. Go to original source...
    3. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115(12):3318-332. Go to original source...
    4. Rudel LL. Preclinical and clinical pharmacology of a new class of lipid manage­ ment agents. Am J Manag Care 2002;8(2 Suppl):S33-35.
    5. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303(5661):1201-1204. Go to original source...
    6. Shepherd J. Lipids in health and disease. Biochem Soc Trans 2004;32(6): 1051-1056. Go to original source...
    7. Kramer W, Glombik H, Petry S, Heuer H, Schäfer H, Wendler W, Corsiero D, Girbig F, Weyland C. Identification of binding proteins for cholesterol absorption inhibitors as components of the intestinal cholesterol transporter. FEBS Lett 2000;487(2):293-297. Go to original source...
    8. van Heek M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively in­ hibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001;134(2):409-417. Go to original source...
    9. Jeu L, Cheng JW. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol - absorption inhibitor. Clin Ther 2003;25(9):2352-2387. Go to original source...
    10. van Heek M, Farley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, Davis HR Jr. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129(8):1748-1754. Go to original source...
    11. Bultas, J. Ezetimib - selektivní inhibitor absorpce cholesterolu. Remedia 2004;14(2):214-216.
    12. Jadhav, SB, Jain, GK. Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 2006;58(1):3-18. Go to original source...
    13. Tintut Y, Parhami F, Tsingotjidou A, Tetradis S, Territo M, Demer LL. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J Biol Chem 2002;277(16):14221-14226. Go to original source...
    14. Tintut Y, Morony S, Demer LL. Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler Tromb Vasc Biol 2004;24(2):e6-10. Go to original source...
    15. Parhami F, Tintut Y, Beamer WG, Gharavi N, Goodman W, Demer LL. Atherogenic high-fat diet reduces bone mineralization in mice. J Bone Miner Res 2001;16:182-188. Go to original source...
    16. Orozco P. Atherogenic lipid profile and elevated lipoproteid (a) are associated with lower bone mineral density in early postmenopausal women. Eur J Epidemiol 2004;19(12):1105-1112. Go to original source...
    17. Tankó LB, Bagger YZ, Nielsen SB, Christiansen C. Does serum cholesterol con­ tribute to vertebral bone loss in postmenopausal women? Bone 2003;32(1):8-14. Go to original source...
    18. Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K. Increased bone turnover in patients with hypercholesterolemia. Endocr J 2008;55(1):143-151. Go to original source...
    19. Lee AJ, Hodges S, Eastell R. Measurement of osteocalcin. Ann Clin Biochem 2000;37(Pt 4):432 446. Go to original source...
    20. Anh DJ, Dimai HP, Hall SL, Farley JR. Skeletal alkaline phosphatase activity is primarily released from human osteoblasts in an insoluble form, and the net rele­ ase is inhibited by calcium and skeletal growth factors. Calcif Tissue Int 1998;62(4):332-340. Go to original source...
    21. Garnero P, Vergnaud P, Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 2008;54(1):188-196. Go to original source...
    22. Herrmann M, Seidel MJ. The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I: a comparative review. Clin Chim Acta 2008;393(2):57-75. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.